EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A step toward defining optimal liposomal amphotericin B treatment duration in pulmonary mucormycosis: results from emulated trials

Anne Coste iD, Olivier Paccoud, François Danion, Anne Conrad, Sylvain Poirée, Amandine Le Bourgeois, Claire Defrance, Valérie Letscher-Bru, Florent Morio iD, Thomas Gastinne, Marie-Elisabeth Bougnoux iD, Felipe Suarez iD und 19 weitere

Antimicrobial Agents and Chemotherapy · 2026

DOI: 10.1128/aac.01523-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2026. Verfasst von Anne Coste und 30 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Department, La Cavale Blanche Hospital, Brest University Hospital, Brest, France. Hauptthemen laut MEDLINE: Mucormycosis, Amphotericin B, Antifungal Agents, Lung Diseases, Fungal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Management of pulmonary mucormycosis includes intravenous liposomal amphotericin-B (L-AmB), followed by posaconazole or isavuconazole. We aimed to determine the optimal L-AmB duration before switching to triazole therapy. Using data from a retrospective study in France, we performed an emulated trial evaluating stopping L-AmB after 14 days (short treatment) versus continuing L-AmB (long treatment). The benefit of combination L-AmB therapy was also investigated. A cloning, censoring, and weighting approach was used to account for immortal time and indication biases. Ninety-four cases of pulmonary mucormycosis were included, of which 35% had dissemination. Eighty-nine patients received L-AmB first-line therapy for a median of 25 (IQR: 12–54) days, including 18 patients as combination therapy. L-AmB was discontinued for adverse events in 16/89 patients (18%). Treatment was switched to posaconazole ( n = 38) or isavuconazole ( n = 9) in 47 cases and was switched back to L-AmB due to disease progression in 11/47 (23%) cases. Overall, the 180-day mortality was 54%. Diagnosis in the ICU, dyspnea at diagnosis, disseminated disease, and ground-glass opacities on chest CT scan were associated with increased mortality. No difference in 180-day survival was found between patients receiving short or long L-AmB treatment (HR=0.80, 95% CI [0.29–1.99]) and between patients receiving L-AmB alone or in combination (HR=1.14, 95% CI [0.56–2.32]) in emulated trials, although confidence intervals were wide. Switching to triazole therapy after 14 days of L-AmB treatment was as effective as longer durations while reducing L-AmB side effects. Combination therapy did not improve prognosis. These results could inform randomized clinical trials assessing different first-line therapeutic strategies for pulmonary mucormycosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MucormycosisAmphotericin BAntifungal AgentsLung Diseases, FungalHumansTriazolesRetrospective StudiesFemaleMaleMiddle AgedNitrilesPyridinesAgedDrug Therapy, CombinationAdult

Stichwörter der Autor:innen

amphotericin Bemulated trialsisavuconazolemucormycosis

Substanzen

Amphotericin BAntifungal Agentsliposomal amphotericin BTriazolesposaconazoleisavuconazoleNitrilesPyridines

Autor:innen und Institutionen

  • Infectious Diseases Department, La Cavale Blanche Hospital, Brest University Hospital, Brest, France.
  • INSERM LaTIM, UMR 1101, Université de Bretagne Occidentale, Brest, France.
  • Infectious Diseases Department, Necker-Enfants Malades Hospital, AP-HP, Paris, France.
  • Institut Pasteur, Université Paris Cité, National Reference Center for Invasive Mycoses and Antifungals, Paris, France.
  • Infectious Diseases Department, Strasbourg University Hospital, Inserm UMR_S 1109, Immuno-rhumatologie Moléculaire, Strasbourg, France.
  • Infectious Diseases Department, Croix Rousse Hospital, Hospices Civils de Lyon, Lyon, France.

ORCID-Profile: Anne Coste, Florent Morio, Marie-Elisabeth Bougnoux, Felipe Suarez, Damien Dupont, Françoise Botterel, Laurence Millon, Fanny Lanternier

Zitieren

APA

Coste, A., Paccoud, O., Danion, F., Conrad, A., Poirée, S., Le Bourgeois, A., Defrance, C., Letscher-Bru, V., Morio, F., Gastinne, T., Bougnoux, M. E., Suarez, F., Le Gal, S., Dupont, D., Ader, F., Halfon-Domenech, C., Ducastelle-Leprêtre, S., Botterel, F., Millon, L., …, & Lanternier, F. (2026). A step toward defining optimal liposomal amphotericin B treatment duration in pulmonary mucormycosis: results from emulated trials. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01523-25

Vancouver

Coste A, Paccoud O, Danion F, Conrad A, Poirée S, Le Bourgeois A, et al. A step toward defining optimal liposomal amphotericin B treatment duration in pulmonary mucormycosis: results from emulated trials. Antimicrobial Agents and Chemotherapy. 2026. doi:10.1128/aac.01523-25

BibTeX
@article{Coste2026,
  author = {Coste, Anne and Paccoud, Olivier and Danion, François and Conrad, Anne and Poirée, Sylvain and Le Bourgeois, Amandine and Defrance, Claire and Letscher-Bru, Valérie and Morio, Florent and Gastinne, Thomas and Bougnoux, Marie-Elisabeth and Suarez, Felipe and Le Gal, Solène and Dupont, Damien and Ader, Florence and Halfon-Domenech, Carine and Ducastelle-Leprêtre, Sophie and Botterel, Françoise and Millon, Laurence and Guillerm, Gaelle and Ansart, Séverine and Boutoille, David and Ledoux, Marie-Pierre and Herbrecht, Jean-Etienne and Robin, Christine and Melica, Giovanna and Garcia-Hermoso, Dea and Lortholary, Olivier and Herbrecht, Raoul and Porcher, Raphaël and Lanternier, Fanny},
  title = {A step toward defining optimal liposomal amphotericin B treatment duration in pulmonary mucormycosis: results from emulated trials},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  doi = {10.1128/aac.01523-25}
}
Kostenlos starten →